Coronavirus disease 2019 , secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a worldwide pandemic, presenting unprecedented challenges to health-care providers and systems. 1 The immunopathogenesis of COVID-19 is intriguing as it involves virus-driven tissue damage intertwined with an uncontrolled inflammatory response, contributing to severity of disease, acute respiratory distress syndrome (ARDS), and multiple organ failure. 2 Hematopoietic cell transplant (HCT) recipients are severely immunocompromised, with increased risk of severe COVID-19 secondary to the myeloablative conditioning regimens, organ damage, and possible immune recovery leading to an exuberant inflammatory reaction. A comprehensive approach to manage HCT recipients with COVID-19 at different stages after HCT (pre-engraftment, early and late post-engraftment) is lacking in terms of the potential role of early or pre-emptive antiviral use and/or immunomodulators that may improve clinical outcomes. In this brief report, we present two patients with COVID-19 pneumonia that occurred during the pre-engraftment period after HCT at our comprehensive cancer center. Additionally, we review the previously reported cases of COVID-19 in adults HCT recipients until December 31st, 2020, for whom sufficient data were available. [3][4][5][6][7][8][9][10][11][12][13]

Cat Scratch Disease (CSD) infrequently mimics malignancy. We reviewed 11 such cases at MD Anderson Cancer Center and an additional 36 reported from the literature. Breast cancer, sarcoma, and lymphoma were the most commonly suspected malignancies. Most patients were young, female, had prior cat exposure and had no systemic symptoms. Regional lymphadenopathy was the most common finding.

Ophthalmic complications in the lung transplant population are a little-known entity. It includes a spectrum of diseases ranging from infections such as cytomegalovirus (CMV) retinitis, herpetic keratitis, Pseudallescheria boydii to non-infectious complications such as posterior subcapsular cataracts (PSCs), cyclosporine retinopathy, and post-transplant lymphoproliferative disorder (PTLD). These diseases can be attributed to high levels of immunosuppression, advanced age, and drug-specific side effects. Underlying comorbidities such as diabetes mellitus may also play a role in the pathogenesis. Patients can present with varied symptoms such as blurry vision, floaters or eye pain. Prompt diagnosis often requires a high index of suspicion. With increasing numbers of transplants being performed worldwide, it is imperative for the pulmonologist and transplant physician to recognize these often subtle symptoms. Any visual symptom should trigger an ophthalmological evaluation in order to manage these complications; some of which pose the risk of systemic dissemination and significant morbidity. The following article provides an indepth review of the common presenting symptoms, treatments and recent advances related to common ophthalmic complications following lung transplantation. While this article focuses on the lung transplant sub-population, the authors would like to point out that some of these complications are shared by other solid-organ transplants as well, by virtue of their shared immunosuppressive therapies.